Clinical outcomes of the resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis

OBJECTIVES This study sought to assess the clinical safety and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in patients with in-stent restenosis (ISR) from 2 large trials. BACKGROUND ISR treatment is associated with higher rates of subsequent cardiac events compared with treatment of de novo lesions. Although drug-eluting stents (DES) are an option, second-generation DES are largely untested in the treatment of ISR. METHODS A total of 3,489 patients were pooled from the RAC (RESOLUTE All Comers) trial and the RESOLUTE International (RINT) registry. Two-year clinical endpoints included clinically driven target lesion revascularization (TLR), target lesion failure (TLF), cardiac death (CD), target vessel myocardial infarction (TVMI), combined CD or TVMI (CD/TVMI), and Academic Research Consortium definite and probable stent thrombosis (ST). RESULTS Overall, 281 patients (8.1%) received an R-ZES for ISR. Two-year TLR and TLF rates were significantly higher in ISR patients than in non-ISR patients (TLR: 12.7% vs. 4.3%, p = 0.003; TLF: 17.4% vs. 9.4%, p = 0.007); however, the CD/TVMI rate was not (6.9% vs. 6.1%, p = 0.711). Seven ISR patients had ST. Two-year outcomes by ISR stent type were similar: bare-metal stent (BMS)-ISR TLR was 12.5% and TLF was 17.2%; DES-ISR TLR was 13.0% and TLF was 18.8%. CD/TVMI was 7.3% and 7.2% for BMS-ISR and DES-ISR, respectively. CONCLUSIONS Using R-ZES to treat ISR appears equally safe in BMS-ISR and DES-ISR, with CD/TVMI rates comparable to 2-year outcomes in other clinical trials. Although revascularization rates are still higher in ISR lesions, the R-ZES offers an effective alternative for treatment of BMS-ISR and DES-ISR. (Randomized, Two-Arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent [RESOLUTE-AC]; NCT00617084; and RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population [RINT]; NCT00752128).

Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial

OBJECTIVE We investigated clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES). DESIGN Post hoc analysis of a randomised, multicentre, non-inferiority trial. SETTING Multicentre study. PATIENTS All comers study with minimal exclusion criteria. INTERVENTIONS Patients were treated with either zotarolimus or everolimus eluting stents. The patient population was divided according to treatment of bifurcation or non-bifurcation lesions and clinical outcomes were compared between groups. MAIN OUTCOMES MEASURES Clinical outcomes within 2-year follow-up. RESULTS A total of 2265 patients were included in the present analysis. Two-year follow-up data were available in 2223 patients: 1838 patients in the non-bifurcation group and 385 patients in the bifurcation group. At 2-year follow-up the bifurcation and the non-bifurcation lesion groups showed no significant differences in terms of cardiac death (2.3 vs 2.1, p=0.273), target lesion failure (9.7% vs 13.8%, p=0.255), major adverse cardiac events (11.5% vs 15.1%, p=0.305), target lesion revascularisation (4.7% vs 6.0%, p=0.569), and definite or probable stent thrombosis (1.6% vs 1.8%, p=0.419). CONCLUSIONS The use of second generation DES for the treatment of coronary bifurcation lesions was associated with similar long term mortality and clinical outcomes compared with non-bifurcation lesions.

Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program

BACKGROUND Outcome data are limited in patients with ST-segment elevation acute myocardial infarction (STEMI) or other acute coronary syndromes (ACSs) who receive a drug-eluting stent (DES). Data suggest that first generation DES is associated with an increased risk of stent thrombosis when used in STEMI. Whether this observation persists with newer generation DES is unknown. The study objective was to analyze the two-year safety and effectiveness of Resolute™ zotarolimus-eluting stents (R-ZESs) implanted for STEMI, ACS without ST segment elevation (non-STEACS), and stable angina (SA). METHODS Data from the Resolute program (Resolute All Comers and Resolute International) were pooled and patients with R-ZES implantation were categorized by indication: STEMI (n=335), non-STEACS (n=1416), and SA (n=1260). RESULTS Mean age was 59.8±11.3 years (STEMI), 63.8±11.6 (non-STEACS), and 64.9±10.1 (SA). Fewer STEMI patients had diabetes (19.1% vs. 28.5% vs. 29.2%; P<0.001), prior MI (11.3% vs. 27.2% vs. 29.4%; P<0.001), or previous revascularization (11.3% vs. 27.9% vs. 37.6%; P<0.001). Two-year definite/probable stent thrombosis occurred in 2.4% (STEMI), 1.2% (non-STEACS) and 1.1% (SA) of patients with late/very late stent thrombosis (days 31-720) rates of 0.6% (STEMI and non-STEACS) and 0.4% (SA) (P=NS). The two-year mortality rate was 2.1% (STEMI), 4.8% (non-STEACS) and 3.7% (SA) (P=NS). Death or target vessel re-infarction occurred in 3.9% (STEMI), 8.7% (non-STEACS) and 7.3% (SA) (P=0.012). CONCLUSION R-ZES in STEMI and in other clinical presentations is effective and safe. Long term outcomes are favorable with an extremely rare incidence of late and very late stent thrombosis following R-ZES implantation across indications.

Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program

OBJECTIVES The aim of this study was to describe the process to obtain Food and Drug Administration (FDA) approval for the expanded indication for treatment with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Inc., Santa Rosa, California) in patients with coronary artery disease and diabetes. BACKGROUND The R-ZES is the first drug-eluting stent specifically indicated in the United States for percutaneous coronary intervention in patients with diabetes. METHODS We pooled patient-level data for 5,130 patients from the RESOLUTE Global Clinical Program. A performance goal prospectively determined in conjunction with the FDA was established as a rate of target vessel failure at 12 months of 14.5%. In addition to the FDA pre-specified cohort of less complex patients with diabetes (n = 878), we evaluated outcomes of the R-ZES in all 1,535 patients with diabetes compared with all 3,595 patients without diabetes at 2 years. RESULTS The 12-month rate of target vessel failure in the pre-specified diabetic cohort was 7.8% (upper 95% confidence interval: 9.51%), significantly lower than the performance goal of 14.5% (p < 0.001). After 2 years, the cumulative incidence of target lesion failure in patients with noninsulin-treated diabetes was comparable to that of patients without diabetes (8.0% vs. 7.1%). The higher risk insulin-treated population demonstrated a significantly higher target lesion failure rate (13.7%). In the whole population, including complex patients, rates of stent thrombosis were not significantly different between patients with and without diabetes (1.2% vs. 0.8%). CONCLUSIONS The R-ZES is safe and effective in patients with diabetes. Long-term clinical data of patients with noninsulin-treated diabetes are equivalent to patients without diabetes. Patients with insulin-treated diabetes remain a higher risk subset. (The Medtronic RESOLUTE Clinical Trial; NCT00248079; Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent [RESOLUTE-AC]; NCT00617084; The Medtronic RESOLUTE US Clinical Trial (R-US); NCT00726453; RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population [R-Int]; NCT00752128; RESOLUTE Japan-The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent [RJ]; NCT00927940).

Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program

BACKGROUND Overlapping first generation sirolimus- and paclitaxel-eluting stents are associated with persistent inflammation, fibrin deposition and delayed endothelialisation in preclinical models, and adverse angiographic and clinical outcomes--including death and myocardial infarction (MI)--in clinical studies. OBJECTIVES To establish as to whether there are any safety concerns with newer generation drug-eluting stents (DES). DESIGN Propensity score adjustment of baseline anatomical and clinical characteristics were used to compare clinical outcomes (Kaplan-Meier estimates) between patients implanted with overlapping DES (Resolute zotarolimus-eluting stent (R-ZES) or R-ZES/other DES) against no overlapping DES. Additionally, angiographic outcomes for overlapping R-ZES and everolimus-eluting stents were evaluated in the randomised RESOLUTE All-Comers Trial. SETTING Patient level data from five controlled studies of the RESOLUTE Global Clinical Program evaluating the R-ZES were pooled. Enrollment criteria were generally unrestrictive. PATIENTS 5130 patients. MAIN OUTCOME MEASURES 2-year clinical outcomes and 13-month angiographic outcomes. RESULTS 644 of 5130 patients (12.6%) in the RESOLUTE Global Clinical Program underwent overlapping DES implantation. Implantation of overlapping DES was associated with an increased frequency of MI and more complex/calcified lesion types at baseline. Adjusted in-hospital, 30-day and 2-year clinical outcomes indicated comparable cardiac death (2-year overlap vs non-overlap: 3.0% vs 2.1%, p=0.36), major adverse cardiac events (13.3% vs 10.7%, p=0.19), target-vessel MI (3.9% vs 3.4%, p=0.40), clinically driven target vessel revascularisation (7.7% vs 6.5%, p=0.32), and definite/probable stent thrombosis (1.4% vs 0.9%, p=0.28). 13-month adjusted angiographic outcomes were comparable between overlapping and non-overlapping DES. CONCLUSIONS Overlapping newer generation DES are safe and effective, with comparable angiographic and clinical outcomes--including repeat revascularisation--to non-overlapping DES.

Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention

Aims: To compare clinical outcomes after percutaneous coronary intervention (PCI) between patients with acute coronary syndromes (ACS) and those with stable ischaemic heart disease (SIHD) stratified by anatomic disease complexity (SYNTAX score). Methods and results: Patient-level data from three all-comers PCI trials were pooled. Patients (n=4,204) were stratified by clinical presentation (i.e., ACS or SIHD) and by SYNTAX score (i.e., lowest vs. two highest tertiles). The major adverse cardiac event (MACE) rates of patients with low-risk SIHD (n=531) and high-risk SIHD (n=1,066) were compared with ACS patients (n=2,607), respectively. At two years, the risk of MACE was higher for high-risk SIHD patients (OR 1.34, 95% CI: 1.08-1.66) and lower for low-risk SIHD patients (OR 0.61, 95% CI: 0.43-0.87) compared with ACS patients, respectively. This difference between high-risk SIHD patients and ACS patients was primarily driven by a higher risk of myocardial infarction (OR 1.64, 95% CI: 1.21-2.21), while there was no difference for cardiac death (OR 0.77, 95% CI: 0.49-1.21) or target lesion revascularisation (OR 1.21, 95% CI: 0.91-1.62). Conclusions: In this pooled analysis, the majority of patients undergoing PCI for SIHD (i.e., with SYNTAX score >8) had a higher risk of MACE than patients with ACS. Trial registration: URL: http://www.ClinicalTrials.gov; unique identifier: NCT00297661 (Sirtax), NCT00389220 (Leaders), NCT00114972 (Resolute-AC).

Schmiede ─ Heiligtum ─ Wassermühle. Cham-Hagendorn (Kanton Zug) in römischer Zeit. Ausgrabungen 1944/45 und 2003/04

1944/1945 wurde in Cham-Hagendorn eine Wassermühle ausgegraben, die dank ihrer aussergewöhnlich guten Holzerhaltung seit langem einen prominenten Platz in der Forschung einnimmt. 2003 und 2004 konnte die Kantonsarchäologie Zug den Platz erneut archäologisch untersuchen. Dabei wurden nicht nur weitere Reste der Wassermühle, sondern auch Spuren älterer und jüngerer Anlagen geborgen: eine ältere und eine jüngere Schmiedewerkstatt (Horizont 1a/Horizont 3) sowie ein zweiphasiges Heiligtum (Horizonte 1a/1b). All diese Anlagen lassen sich nun in das in den neuen Grabungen erkannte stratigraphische Gerüst einhängen (s. Beil. 2). Dank der Holzerhaltung können die meisten Phasen dendrochronologisch datiert werden (s. Abb. 4.1/1a): Horizont 1a mit Schlagdaten zwischen 162(?)/173 und 200 n. Chr., Horizont 1b um 215/218 n. Chr. und Horizont 2 um 231 n. Chr. Ferner konnten in den neuen Grabungen Proben für mikromorphologische und archäobotanische Untersuchungen entnommen werden (Kap. 2.2; 3.11). In der vorliegenden Publikation werden der Befund und die Baustrukturen vorgelegt, (Kap. 2), desgleichen sämtliche stratifizierten Funde und eine umfassende Auswahl der 1944/1945 geborgenen Funde (Kap. 3). Dank anpassender Fragmente, sog. Passscherben, lassen sich diese zum Teil nachträglich in die Schichtenabfolge einbinden. Die mikromorphologischen und die archäobotanischen Untersuchungen (Kap. 2.2; 3.11) zeigen, dass der Fundplatz in römischer Zeit inmitten einer stark vom Wald und dem Fluss Lorze geprägten Landschaft lag. In unmittelbarer Nähe können weder eine Siedlung noch einzelne Wohnbauten gelegen haben. Die demnach nur gewerblich und sakral genutzten Anlagen standen an einem Bach, der vermutlich mit jenem Bach identisch ist, der noch heute das Groppenmoos entwässert und bei Cham-Hagendorn in die Lorze mündet (s. Abb. 2.4/1). Der antike Bach führte wiederholt Hochwasser ─ insgesamt sind fünf grössere Überschwemmungsphasen auszumachen (Kap. 2.2; 2.4). Wohl anlässlich eines Seehochstandes durch ein Überschwappen der Lorze in den Bach ausgelöst, müssen diese Überschwemmungen eine enorme Gewalt entwickelt haben, der die einzelnen Anlagen zum Opfer fielen. Wie die Untersuchung der Siedlungslandschaft römischer Zeit rund um den Zugersee wahrscheinlich macht (Kap. 6 mit Abb. 6.2/2), dürften die Anlagen von Cham-Hagendorn zu einer in Cham-Heiligkreuz vermuteten Villa gehören, einem von fünf grösseren Landgütern in diesem Gebiet. Hinweise auf Vorgängeranlagen fehlen, mit denen die vereinzelten Funde des 1. Jh. n. Chr. (Kap. 4.5) in Verbindung gebracht werden könnten. Diese dürften eher von einer der Überschwemmungen bachaufwärts weggerissen und nach Cham-Hagendorn eingeschwemmt worden sein. Die Nutzung des Fundplatzes (Horizont 1a; s. Beil. 6) setzte um 170 n. Chr. mit einer Schmiedewerkstatt ein (Kap. 2.5.1). Der Fundanfall, insbesondere die Schmiedeschlacken (Kap. 3.9) belegen, dass hier nur hin und wieder Geräte hergestellt und repariert wurden (Kap. 5.2). Diese Werkstatt war vermutlich schon aufgelassen und dem Verfall preisgegeben, als man 200 n. Chr. (Kap. 4.2.4) auf einer Insel zwischen dem Bach und einem Lorzearm ein Heiligtum errichtete (Kap. 5.3). Beleg für den sakralen Status dieser Insel ist in erster Linie mindestens ein eigens gepflanzter Pfirsichbaum, nachgewiesen mit Pollen, einem Holz und über 400 Pfirsichsteinen (Kap. 3.11). Die im Bach verlaufende Grenze zwischen dem sakralen Platz und der profanen Umgebung markierte man zusätzlich mit einer Pfahlreihe (Kap. 2.5.3). In diese war ein schmaler Langbau integriert (Kap. 2.5.2), der an die oft an Temenosmauern antiker Heiligtümer angebauten Portiken erinnert und wohl auch die gleiche Funktion wie diese gehabt hatte, nämlich das Aufbewahren von Weihegaben und Kultgerät (Kap. 5.3). Das reiche Fundmaterial, das sich in den Schichten der ersten Überschwemmung fand (s. Abb. 5./5), die um 205/210 n. Chr. dieses Heiligtum zerstört hatte, insbesondere die zahlreiche Keramik (Kap. 3.2.4), und die zum Teil auffallend wertvollen Kleinfunde (Kap. 3.3.3), dürften zum grössten Teil einst in diesem Langbau untergebracht gewesen sein. Ein als Glockenklöppel interpretiertes, stratifiziertes Objekt spricht dafür, dass die fünf grossen, 1944/1945 als Stapel aufgefundenen Eisenglocken vielleicht auch dem Heiligtum zuzuweisen sind (Kap. 3.4). In diesen Kontext passen zudem die überdurchschnittlich häufig kalzinierten Tierknochen (Kap. 3.10). Nach der Überschwemmung befestigte man für 215 n. Chr. (Kap. 4.2.4) das unterspülte Bachufer mit einer Uferverbauung (Kap. 2.6.1). Mit dem Bau eines weiteren, im Bach stehenden Langbaus (Kap. 2.6.2) stellte man 218 n. Chr. das Heiligtum auf der Insel in ähnlicher Form wieder her (Horizont 1b; s. Beil. 7). Von der Pfahlreihe, die wiederum die sakrale Insel von der profanen Umgebung abgrenzte, blieben indes nur wenige Pfähle erhalten. Dennoch ist der sakrale Charakter der Anlage gesichert. Ausser dem immer noch blühenden Pfirsichbaum ist es ein vor dem Langbau aufgestelltes Ensemble von mindestens 23 Terrakottafigurinen (s. Abb. 3.6/1), elf Veneres, zehn Matres, einem Jugendlichen in Kapuzenmantel und einem kindlichen Risus (Kap. 3.6; s. auch Kap. 2.6.3). In den Sedimenten der zweiten Überschwemmung, der diese Anlage um 225/230 n. Chr. zum Opfer gefallen war, fanden sich wiederum zahlreiche Keramikgefässe (Kap. 3.2.4) und zum Teil wertvolle Kleinfunde wie eine Glasperle mit Goldfolie (Kap. 3.8.2) und eine Fibel aus Silber (Kap. 3.3.3), die wohl ursprünglich im Langbau untergebracht waren (Kap. 5.3.2 mit Abb. 5/7). Weitere Funde mit sicherem oder möglichem sakralem Charakter finden sich unter den 1944/1945 geborgenen Funden (s. Abb. 5/8), etwa ein silberner Fingerring mit Merkurinschrift, ein silberner Lunula-Anhänger, eine silberne Kasserolle (Kap. 3.3.3), eine Glasflasche mit Schlangenfadenauflage (Kap. 3.8.2) und einige Bergkristalle (Kap. 3.8.4). Im Bereich der Terrakotten kamen ferner mehrere Münzen (Kap. 3.7) zum Vorschein, die vielleicht dort niedergelegt worden waren. Nach der zweiten Überschwemmung errichtete man um 231 n. Chr. am Bach eine Wassermühle (Horizont 2; Kap. 2.7; Beil. 8; Abb. 2.7/49). Ob das Heiligtum auf der Insel wieder aufgebaut oder aufgelassen wurde, muss mangels Hinweisen offen bleiben. Für den abgehobenen Zuflusskanal der Wassermühle verwendete man mehrere stehen gebliebene Pfähle der vorangegangenen Anlagen der Horizonte 1a und 1b. Obwohl die Wassermühle den 28 jährlichen Überschwemmungshorizonten (Kap. 2.2) und den Funden (Kap. 4.3.2; 4.4.4; 45) zufolge nur bis um 260 n. Chr., während gut einer Generation, bestand, musste sie mindestens zweimal erneuert werden – nachgewiesen sind drei Wasserräder, drei Mühlsteinpaare und vermutlich drei Podeste, auf denen jeweils das Mahlwerk ruhte. Grund für diese Umbauten war wohl der weiche, instabile Untergrund, der zu Verschiebungen geführt hatte, so dass das Zusammenspiel von Wellbaum bzw. Sternnabe und Übersetzungsrad nicht mehr funktionierte und das ganze System zerbrach. Die Analyse von Pollen aus dem Gehhorizont hat als Mahlgut Getreide vom Weizentyp nachgewiesen (Kap. 3.11.4). Das Abzeichen eines Benefiziariers (Kap. 3.3.2 mit Abb. 3.3/23,B71) könnte dafür sprechen, dass das verarbeitete Getreide zumindest zum Teil für das römische Militär bestimmt war (s. auch Kap. 6.2.3). Ein im Horizont 2 gefundener Schreibgriffel und weitere stili sowie eine Waage für das Wägen bis zu 35-40 kg schweren Waren aus dem Fundbestand von 1944/1945 könnten davon zeugen, dass das Getreide zu wägen und zu registrieren war (Kap. 3.4.2). Kurz nach 260 n. Chr. fiel die Wassermühle einem weiteren Hochwasser zum Opfer. Für den folgenden Horizont 3 (Beil. 9) brachte man einen Kiesboden ein und errichtete ein kleines Gebäude (Kap. 2.8). Hier war wohl wiederum eine Schmiede untergebracht, wie die zahlreichen Kalottenschlacken belegen (Kap. 3.9), die im Umfeld der kleinen Baus zum Vorschein kamen. Aufgrund der Funde (Kap. 4.4.4; 4.5) kann diese Werkstatt nur kurze Zeit bestanden haben, höchstens bis um 270 n. Chr., bevor sie einem weiteren Hochwasser zum Opfer fiel. Von der jüngsten Anlage, die wohl noch in römische Zeit datiert (Horizont 4; Beil. 10), war lediglich eine Konstruktion aus grossen Steinplatten zu fassen (Kap. 2.9.1). Wozu sie diente, muss offen bleiben. Auch der geringe Fundanfall spricht dafür, dass die Nutzung des Platzes, zumindest für die römische Zeit, allmählich ein Ende fand (Kap. 4.5). Zu den jüngsten Strukturen gehören mehrere Gruben (Kap. 2.9.2), die vielleicht der Lehmentnahme dienten. Mangels Funden bleibt ihre Datierung indes ungewiss. Insbesondere wissen wir nicht, ob sie noch in römische Zeit datieren oder jünger sind. Spätestens mit der fünften Überschwemmung, die zur endgültigen Verlandung führte und wohl schon in die frühe Neuzeit zu setzen ist, wurde der Platz aufgelassen und erst mit dem Bau der bestehenden Fensterfabrik Baumgartner wieder besetzt.

The Impact of Renal Impairment on Long-Term Safety and Effectiveness of Drug-Eluting Stents

BACKGROUND Renal impairment (RI) is associated with impaired prognosis in patients with coronary artery disease. Clinical and angiographic outcomes of patients undergoing percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES) in this patient population are not well established. METHODS We pooled individual data for 5,011 patients from 3 trials with the exclusive and unrestricted use of DES (SIRTAX - N = 1,012, LEADERS - N = 1,707, RESOLUTE AC - N = 2,292). Angiographic follow-up was available for 1,544 lesions. Outcomes through 2 years were stratified according to glomerular filtration rate (normal renal function: GFR≥90 ml/min; mild RI: 90

Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions.

AIMS To investigate the outcomes of percutaneous coronary intervention (PCI) in bifurcation versus non-bifurcation lesions using the next-generation Resolute zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS We analyzed 3-year pooled data from the RESOLUTE All-Comers trial and the RESOLUTE International registry. The R-ZES was used in 2772 non-bifurcation lesion patients and 703 bifurcation lesion patients, of which 482 were treated with a simple-stent technique (1 stent used to treat the bifurcation lesion) and 221 with a complex bifurcation technique (2 or more stents used). The primary endpoint was 3-year target lesion failure (TLF, defined as the composite of death from cardiac causes, target vessel myocardial infarction, or clinically-indicated target lesion revascularization [TLR]), and was 13.3% in bifurcation vs 11.3% in non-bifurcation lesion patients (adjusted P=.06). Landmark analysis revealed that this difference was driven by differences in the first 30 days between bifurcation vs non-bifurcation lesions (TLF, 6.6% vs 2.7%, respectively; adjusted P<.001), which included significant differences in each component of TLF and in-stent thrombosis. Between 31 days and 3 years, TLF, its components, and stent thrombosis did not differ significantly between bifurcation lesions and non-bifurcation lesions (TLF, 7.7% vs 9.0%, respectively; adjusted P=.50). CONCLUSION The 3-year risk of TLF following PCI with R-ZES in bifurcation lesions was not significantly different from non-bifurcation lesions. However, there was an increased risk associated with bifurcation lesions during the first 30 days; beyond 30 days, bifurcation lesions and non-bifurcation lesions yielded similar 3-year outcomes.

Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.

Aims: We conducted a pooled post hoc analysis (RESOLUTE All Comers and RESOLUTE International) of patients who had the Resolute® zotarolimus-eluting stent (R-ZES) implanted in revascularised total occlusions (TO) compared with patients treated with R-ZES for non-occluded lesions. Methods and results: Patients were divided into three groups: chronic TO (CTO; n=256), non-chronic TO (n=292), and no occlusion (n=2,941). Clinical and safety outcomes assessed through two years included target lesion failure (TLF: cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation) and Academic Research Consortium definite or probable stent thrombosis. The rate of TLF at two years was not significantly different among patients in the CTO (9.1%), TO (9.8%), and no occlusion (10.4%) groups (log-rank p=0.800); neither were the components of TLF. Definite or probable stent thrombosis occurred more frequently in the TO group (2.8% vs. 1.2% in the CTO and 1.1% in the group with no occlusion, p=0.027). There were 10 late and six very late stent thrombosis events. Conclusions: Apart from a higher rate of stent thrombosis in patients with TO, patients with totally occluded coronary arteries who receive revascularisation with an R-ZES have clinical outcomes comparable to those who receive a similar stent in non-occluded lesions.

Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials

OBJECTIVE To investigate the long-term prognostic implications of coronary calcification in patients undergoing percutaneous coronary intervention for obstructive coronary artery disease. METHODS Patient-level data from 6296 patients enrolled in seven clinical drug-eluting stents trials were analysed to identify in angiographic images the presence of severe coronary calcification by an independent academic research organisation (Cardialysis, Rotterdam, The Netherlands). Clinical outcomes at 3-years follow-up including all-cause mortality, death-myocardial infarction (MI), and the composite end-point of all-cause death-MI-any revascularisation were compared between patients with and without severe calcification. RESULTS Severe calcification was detected in 20% of the studied population. Patients with severe lesion calcification were less likely to have undergone complete revascularisation (48% vs 55.6%, p<0.001) and had an increased mortality compared with those without severely calcified arteries (10.8% vs 4.4%, p<0.001). The event rate was also high in patients with severely calcified lesions for the combined end-point death-MI (22.9% vs 10.9%; p<0.001) and death-MI- any revascularisation (31.8% vs 22.4%; p<0.001). On multivariate Cox regression analysis, including the Syntax score, the presence of severe coronary calcification was an independent predictor of poor prognosis (HR: 1.33 95% CI 1.00 to 1.77, p=0.047 for death; 1.23, 95% CI 1.02 to 1.49, p=0.031 for death-MI, and 1.18, 95% CI 1.01 to 1.39, p=0.042 for death-MI- any revascularisation), but it was not associated with an increased risk of stent thrombosis. CONCLUSIONS Patients with severely calcified lesions have worse clinical outcomes compared to those without severe coronary calcification. Severe coronary calcification appears as an independent predictor of worse prognosis, and should be considered as a marker of advanced atherosclerosis.

Performance of the resolute zotarolimus-eluting stent in small vessels.

BACKGROUND Drug eluting stents for the treatment of small vessel coronary artery disease have traditionally yielded inferior clinical outcomes compared to the use of DES in large vessels. The benefit of the second-generation Resolute zotarolimus-eluting stent (R-ZES) in small vessels was examined. METHODS Two-year clinical outcomes from five combined R-ZES studies were compared between patients with small (reference vessel diameter [RVD] ≤2.5 mm; n = 1,956) and large (RVD >2.5 mm; n = 3174) vessels. RESULTS Despite a higher incidence of comorbidities in the small vessel group, there was no significant difference in target lesion failure (TLF) (10.1% vs. 8.7%; P = 0.54) at 2 years. When the subgroup of patients with diabetes was examined (n = 1,553) there was no significant difference in 2-year TLF in small compared to large vessels (11.2% vs. 11.1%; P = 0.17). Similarly, within the small vessel cohort, no significant difference was seen regarding TLF at 2 years between people with and without diabetes (11.2% vs 9.6%; P = 0.28). CONCLUSION When used for the treatment of small vessels, the R-ZES appears to provide acceptable clinical results at 2 years when compared to its performance in large vessels.

4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)

OBJECTIVES The aim of the study was to investigate 4-year outcomes and predictors of repeat revascularization in patients treated with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Minneapolis, Minnesota) and XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the RESOLUTE (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) All-Comers trial. BACKGROUND Data on long-term outcomes of new-generation drug-eluting stents are limited, and predictors of repeat revascularization due to restenosis and/or progression of disease are largely unknown. METHODS Patients were randomly assigned to treatment with the R-ZES (n = 1,140) or the EES (n = 1,152). We assessed pre-specified safety and efficacy outcomes at 4 years including target lesion failure and stent thrombosis. Predictors of revascularization at 4 years were identified by Cox regression analysis. RESULTS At 4 years, the rates of target lesion failure (15.2% vs. 14.6%, p = 0.68), cardiac death (5.4% vs. 4.7%, p = 0.44), and target vessel myocardial infarction (5.3% vs. 5.4%, p = 1.00), clinically-indicated target lesion revascularization (TLR) (7.0% vs. 6.5%, p = 0.62), and definite/probable stent thrombosis (2.3% vs. 1.6%, p = 0.23) were similar with the R-ZES and EES. Independent predictors of TLR were age, insulin-treated diabetes, SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score, treatment of saphenous vein grafts, ostial lesions, and in-stent restenosis. Independent predictors of any revascularization were age, diabetes, previous percutaneous coronary intervention, absence of ST-segment elevation myocardial infarction, smaller reference vessel diameter, SYNTAX score, and treatment of left anterior descending, right coronary artery, saphenous vein grafts, ostial lesions, or in-stent restenosis. CONCLUSIONS R-ZES and EES demonstrated similar safety and efficacy throughout 4 years. TLR represented less than one-half of all repeat revascularization procedures. Patient- and lesion-related factors predicting the risk of TLR and any revascularization showed considerable overlap. (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention [RESOLUTE-AC]; NCT00617084).

Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.

AIM The optimal duration of dual antiplatelet therapy (DAPT) following the use of new generation drug-eluting stents is unknown. METHODS AND RESULTS The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme. Daily acetylsalicylate (ASA) and a thienopyridine for 6-12 months were prescribed. A DAPT interruption was defined as any interruption of ASA and/or a thienopyridine of >1 day; long interruptions were >14 days. Three groups were analysed: no interruption, interruption during the first month, and >1-12 months. There were 1069 (21.83%) patients with a DAPT interruption and 3827 patients with no interruption. Among the 166 patients in the 1-month interruption group, 6 definite/probable ST events occurred (3.61%; all long DAPT interruptions), and among the 903 patients in the >1-12 months (60% occurred between 6 and 12 months) interruption group, 1 ST event occurred (0.11%; 2-day DAPT interruption). Among patients with no DAPT interruption, 32 ST events occurred (0.84%). Rates of CD/TVMI were 6.84% in the 1-month long interruption group, 1.41% in the >1-12 months long interruption group, and 4.08% in patients on continuous DAPT. CONCLUSION In a pooled population of patients receiving an R-ZES, DAPT interruptions within 1 month are associated with a high risk of adverse outcomes. Dual antiplatelet therapy interruptions between 1 and 12 months were associated with low rates of ST and adverse cardiac outcomes. Randomized clinical trials are needed to determine whether early temporary or permanent interruption of DAPT is truly safe. CLINICAL TRIALSGOV IDENTIFIERS NCT00617084; NCT00726453; NCT00752128; NCT00927940.

Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.

OBJECTIVES The purpose of this study was to compare the 2-year safety and effectiveness of new- versus early-generation drug-eluting stents (DES) according to the severity of coronary artery disease (CAD) as assessed by the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score. BACKGROUND New-generation DES are considered the standard-of-care in patients with CAD undergoing percutaneous coronary intervention. However, there are few data investigating the effects of new- over early-generation DES according to the anatomic complexity of CAD. METHODS Patient-level data from 4 contemporary, all-comers trials were pooled. The primary device-oriented clinical endpoint was the composite of cardiac death, myocardial infarction, or ischemia-driven target-lesion revascularization (TLR). The principal effectiveness and safety endpoints were TLR and definite stent thrombosis (ST), respectively. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated at 2 years for overall comparisons, as well as stratified for patients with lower (SYNTAX score ≤11) and higher complexity (SYNTAX score >11). RESULTS A total of 6,081 patients were included in the study. New-generation DES (n = 4,554) compared with early-generation DES (n = 1,527) reduced the primary endpoint (HR: 0.75 [95% CI: 0.63 to 0.89]; p = 0.001) without interaction (p = 0.219) between patients with lower (HR: 0.86 [95% CI: 0.64 to 1.16]; p = 0.322) versus higher CAD complexity (HR: 0.68 [95% CI: 0.54 to 0.85]; p = 0.001). In patients with SYNTAX score >11, new-generation DES significantly reduced TLR (HR: 0.36 [95% CI: 0.26 to 0.51]; p < 0.001) and definite ST (HR: 0.28 [95% CI: 0.15 to 0.55]; p < 0.001) to a greater extent than in the low-complexity group (TLR pint = 0.059; ST pint = 0.013). New-generation DES decreased the risk of cardiac mortality in patients with SYNTAX score >11 (HR: 0.45 [95% CI: 0.27 to 0.76]; p = 0.003) but not in patients with SYNTAX score ≤11 (pint = 0.042). CONCLUSIONS New-generation DES improve clinical outcomes compared with early-generation DES, with a greater safety and effectiveness in patients with SYNTAX score >11.